Evaluation of leukocyte adherence inhibition (LAI) test in primary and secondary hepatic malignancies

B. V. Tantry, A. K. Jain, Saroj Gupta, J. P. Gupta

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Leukocyte adherence inhibition (LAI) has been demonstrated to be a simple, rapid, and reliable technique in the diagnosis of various malignancies including hepatocellular carcinoma. The LAI test was carried out employing modified tube LAI technique in patients with primary hepatocellular carcinoma (HCC) and secondary carcinomas of liver. Positive LAI response to HCC antigen was obtained in all six (100%) cases of hepatocellular carcinoma tested. None of the control cases, which included 8 healthy subjects and 16 cases of benign liver diseases, gave positive LAI response. Two out of 19 cases of secondary carcinoma gave a positive LAI reaction to HCC antigen. In secondary carcinomas, 19 out of 21 cases (90.48%) gave positive LAI reaction to secondary adenocarcinoma antigen. There were two false positives in controls (1 each of cirrhosis and amebic liver abscess), and 1 out of 8 cases of HCC also gave positive response to secondary carcinoma antigen. Thus, LAI test was found to be useful in the diagnosis of hepatic malignancies.

Original languageEnglish
Pages (from-to)159-162
Number of pages4
JournalJournal of Surgical Oncology
Volume27
Issue number3
DOIs
Publication statusPublished - 01-01-1984

Fingerprint

Leukocyte Adherence Inhibition Test
Hepatocellular Carcinoma
Leukocytes
Liver
Carcinoma
Antigens
Neoplasms
Amoebic Liver Abscess
Liver Diseases
Healthy Volunteers
Adenocarcinoma
Fibrosis

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

@article{41495bd049d240319ab003fc3255a79b,
title = "Evaluation of leukocyte adherence inhibition (LAI) test in primary and secondary hepatic malignancies",
abstract = "Leukocyte adherence inhibition (LAI) has been demonstrated to be a simple, rapid, and reliable technique in the diagnosis of various malignancies including hepatocellular carcinoma. The LAI test was carried out employing modified tube LAI technique in patients with primary hepatocellular carcinoma (HCC) and secondary carcinomas of liver. Positive LAI response to HCC antigen was obtained in all six (100{\%}) cases of hepatocellular carcinoma tested. None of the control cases, which included 8 healthy subjects and 16 cases of benign liver diseases, gave positive LAI response. Two out of 19 cases of secondary carcinoma gave a positive LAI reaction to HCC antigen. In secondary carcinomas, 19 out of 21 cases (90.48{\%}) gave positive LAI reaction to secondary adenocarcinoma antigen. There were two false positives in controls (1 each of cirrhosis and amebic liver abscess), and 1 out of 8 cases of HCC also gave positive response to secondary carcinoma antigen. Thus, LAI test was found to be useful in the diagnosis of hepatic malignancies.",
author = "Tantry, {B. V.} and Jain, {A. K.} and Saroj Gupta and Gupta, {J. P.}",
year = "1984",
month = "1",
day = "1",
doi = "10.1002/jso.2930270306",
language = "English",
volume = "27",
pages = "159--162",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "3",

}

Evaluation of leukocyte adherence inhibition (LAI) test in primary and secondary hepatic malignancies. / Tantry, B. V.; Jain, A. K.; Gupta, Saroj; Gupta, J. P.

In: Journal of Surgical Oncology, Vol. 27, No. 3, 01.01.1984, p. 159-162.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluation of leukocyte adherence inhibition (LAI) test in primary and secondary hepatic malignancies

AU - Tantry, B. V.

AU - Jain, A. K.

AU - Gupta, Saroj

AU - Gupta, J. P.

PY - 1984/1/1

Y1 - 1984/1/1

N2 - Leukocyte adherence inhibition (LAI) has been demonstrated to be a simple, rapid, and reliable technique in the diagnosis of various malignancies including hepatocellular carcinoma. The LAI test was carried out employing modified tube LAI technique in patients with primary hepatocellular carcinoma (HCC) and secondary carcinomas of liver. Positive LAI response to HCC antigen was obtained in all six (100%) cases of hepatocellular carcinoma tested. None of the control cases, which included 8 healthy subjects and 16 cases of benign liver diseases, gave positive LAI response. Two out of 19 cases of secondary carcinoma gave a positive LAI reaction to HCC antigen. In secondary carcinomas, 19 out of 21 cases (90.48%) gave positive LAI reaction to secondary adenocarcinoma antigen. There were two false positives in controls (1 each of cirrhosis and amebic liver abscess), and 1 out of 8 cases of HCC also gave positive response to secondary carcinoma antigen. Thus, LAI test was found to be useful in the diagnosis of hepatic malignancies.

AB - Leukocyte adherence inhibition (LAI) has been demonstrated to be a simple, rapid, and reliable technique in the diagnosis of various malignancies including hepatocellular carcinoma. The LAI test was carried out employing modified tube LAI technique in patients with primary hepatocellular carcinoma (HCC) and secondary carcinomas of liver. Positive LAI response to HCC antigen was obtained in all six (100%) cases of hepatocellular carcinoma tested. None of the control cases, which included 8 healthy subjects and 16 cases of benign liver diseases, gave positive LAI response. Two out of 19 cases of secondary carcinoma gave a positive LAI reaction to HCC antigen. In secondary carcinomas, 19 out of 21 cases (90.48%) gave positive LAI reaction to secondary adenocarcinoma antigen. There were two false positives in controls (1 each of cirrhosis and amebic liver abscess), and 1 out of 8 cases of HCC also gave positive response to secondary carcinoma antigen. Thus, LAI test was found to be useful in the diagnosis of hepatic malignancies.

UR - http://www.scopus.com/inward/record.url?scp=0021688448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021688448&partnerID=8YFLogxK

U2 - 10.1002/jso.2930270306

DO - 10.1002/jso.2930270306

M3 - Article

VL - 27

SP - 159

EP - 162

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 3

ER -